Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases.

Martin W SchoenKenneth R CarsonSeth A EisenCharles L BennettSuhong LuoMelissa A ReimersEric M KnocheAlison L WhitmerYan YanBettina F DrakeKristen M Sanfilippo

Published in: Prostate cancer and prostatic diseases (2022)

Veterans with cardiovascular disease or diabetes had longer treatment duration and OS with enzalutamide compared to abiraterone. Further study of ARTA selection may benefit men with metastatic castrate resistant prostate cancer and likely hormone sensitive prostate cancer, especially among patients with comorbid diseases.

Keyphrases

prostate cancer
cardiovascular disease
radical prostatectomy
squamous cell carcinoma
small cell lung cancer
type diabetes
metabolic syndrome
cardiovascular events
middle aged
skeletal muscle
replacement therapy
weight loss